Literature DB >> 26983820

[Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].

G Gründer1.   

Abstract

The German Act on the Reform of the Market for Medicinal Products (AMNOG) will lead to rapid disappearance of many new psychotropic drugs from the market in Germany over the next few years or their not being introduced in the first place. This article lists the reasons and discusses possible solutions. In the long term, the AMNOG could not only lead to an improvement of psychopharmacology but also contribute to the development of psychiatry as a whole, especially if its standards become an international reference.

Entities:  

Keywords:  Benefit risk assessment; Clinical trial; Drug evaluation; Health technology assessment; Psychopharmacology

Mesh:

Substances:

Year:  2016        PMID: 26983820     DOI: 10.1007/s00115-016-0095-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  17 in total

1.  Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole.

Authors:  Donald C Goff
Journal:  Am J Psychiatry       Date:  2015-09-01       Impact factor: 18.112

Review 2.  Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

Authors:  T Scott Stroup; Wayne M Alves; Robert M Hamer; Jeffrey A Lieberman
Journal:  Nat Rev Drug Discov       Date:  2006-02       Impact factor: 84.694

Review 3.  Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.

Authors:  Tanja Veselinović; Michael Paulzen; Gerhard Gründer
Journal:  Expert Rev Neurother       Date:  2013-11       Impact factor: 4.618

4.  A re-analysis of the reliability of psychiatric diagnosis.

Authors:  R L Spitzer; J L Fleiss
Journal:  Br J Psychiatry       Date:  1974-10       Impact factor: 9.319

5.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

Review 6.  Gene × environment interactions in the prediction of response to antidepressant treatment.

Authors:  Torsten Klengel; Elisabeth B Binder
Journal:  Int J Neuropsychopharmacol       Date:  2012-12-14       Impact factor: 5.176

Review 7.  The multifactorial presentation of depression in acute care.

Authors:  Michael E Thase
Journal:  J Clin Psychiatry       Date:  2013       Impact factor: 4.384

8.  A mega-analysis of genome-wide association studies for major depressive disorder.

Authors:  Stephan Ripke; Naomi R Wray; Cathryn M Lewis; Steven P Hamilton; Myrna M Weissman; Gerome Breen; Enda M Byrne; Douglas H R Blackwood; Dorret I Boomsma; Sven Cichon; Andrew C Heath; Florian Holsboer; Susanne Lucae; Pamela A F Madden; Nicholas G Martin; Peter McGuffin; Pierandrea Muglia; Markus M Noethen; Brenda P Penninx; Michele L Pergadia; James B Potash; Marcella Rietschel; Danyu Lin; Bertram Müller-Myhsok; Jianxin Shi; Stacy Steinberg; Hans J Grabe; Paul Lichtenstein; Patrik Magnusson; Roy H Perlis; Martin Preisig; Jordan W Smoller; Kari Stefansson; Rudolf Uher; Zoltan Kutalik; Katherine E Tansey; Alexander Teumer; Alexander Viktorin; Michael R Barnes; Thomas Bettecken; Elisabeth B Binder; René Breuer; Victor M Castro; Susanne E Churchill; William H Coryell; Nick Craddock; Ian W Craig; Darina Czamara; Eco J De Geus; Franziska Degenhardt; Anne E Farmer; Maurizio Fava; Josef Frank; Vivian S Gainer; Patience J Gallagher; Scott D Gordon; Sergey Goryachev; Magdalena Gross; Michel Guipponi; Anjali K Henders; Stefan Herms; Ian B Hickie; Susanne Hoefels; Witte Hoogendijk; Jouke Jan Hottenga; Dan V Iosifescu; Marcus Ising; Ian Jones; Lisa Jones; Tzeng Jung-Ying; James A Knowles; Isaac S Kohane; Martin A Kohli; Ania Korszun; Mikael Landen; William B Lawson; Glyn Lewis; Donald Macintyre; Wolfgang Maier; Manuel Mattheisen; Patrick J McGrath; Andrew McIntosh; Alan McLean; Christel M Middeldorp; Lefkos Middleton; Grant M Montgomery; Shawn N Murphy; Matthias Nauck; Willem A Nolen; Dale R Nyholt; Michael O'Donovan; Högni Oskarsson; Nancy Pedersen; William A Scheftner; Andrea Schulz; Thomas G Schulze; Stanley I Shyn; Engilbert Sigurdsson; Susan L Slager; Johannes H Smit; Hreinn Stefansson; Michael Steffens; Thorgeir Thorgeirsson; Federica Tozzi; Jens Treutlein; Manfred Uhr; Edwin J C G van den Oord; Gerard Van Grootheest; Henry Völzke; Jeffrey B Weilburg; Gonneke Willemsen; Frans G Zitman; Benjamin Neale; Mark Daly; Douglas F Levinson; Patrick F Sullivan
Journal:  Mol Psychiatry       Date:  2012-04-03       Impact factor: 15.992

Review 9.  Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.

Authors:  Taro Kishi; Shinji Matsunaga; Nakao Iwata
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

Review 10.  The genetics of major depression.

Authors:  Jonathan Flint; Kenneth S Kendler
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.